Kurt Brunner

3.1k total citations
82 papers, 1.7k citations indexed

About

Kurt Brunner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Kurt Brunner has authored 82 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Kurt Brunner's work include Cancer Treatment and Pharmacology (19 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (11 papers). Kurt Brunner is often cited by papers focused on Cancer Treatment and Pharmacology (19 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (11 papers). Kurt Brunner collaborates with scholars based in Switzerland, United States and Italy. Kurt Brunner's co-authors include Roland Sonntag, R Joss, Franco Cavalli, Aron Goldhirsch, F. Cavalli, G Martz, H. J. Senn, Harold O. Douglass, Philip T. Lavin and Paul F. Engstrom and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Kurt Brunner

76 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kurt Brunner Switzerland 23 818 504 452 353 274 82 1.7k
Mario V. Fiorentino Italy 23 554 0.7× 278 0.6× 452 1.0× 320 0.9× 298 1.1× 80 1.7k
D.Th. Sleijfer Netherlands 28 687 0.8× 893 1.8× 339 0.8× 550 1.6× 103 0.4× 74 2.1k
Stephen Shibata United States 28 1.2k 1.4× 545 1.1× 601 1.3× 433 1.2× 226 0.8× 84 2.2k
P. Fargeot France 30 1.7k 2.1× 564 1.1× 575 1.3× 355 1.0× 899 3.3× 87 2.7k
Miriam Tucker United States 7 951 1.2× 218 0.4× 401 0.9× 524 1.5× 337 1.2× 8 1.9k
Robert M. OʼBryan United States 18 960 1.2× 301 0.6× 636 1.4× 215 0.6× 212 0.8× 44 1.5k
L H Einhorn United States 21 1.5k 1.8× 875 1.7× 1.3k 2.9× 666 1.9× 157 0.6× 31 2.7k
Jean-Pierre Droz France 12 795 1.0× 383 0.8× 575 1.3× 203 0.6× 144 0.5× 12 2.0k
John F. Hannigan United States 18 713 0.9× 638 1.3× 552 1.2× 200 0.6× 94 0.3× 30 1.9k
H. Curé France 22 1.2k 1.5× 367 0.7× 327 0.7× 183 0.5× 742 2.7× 82 2.0k

Countries citing papers authored by Kurt Brunner

Since Specialization
Citations

This map shows the geographic impact of Kurt Brunner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt Brunner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt Brunner more than expected).

Fields of papers citing papers by Kurt Brunner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt Brunner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt Brunner. The network helps show where Kurt Brunner may publish in the future.

Co-authorship network of co-authors of Kurt Brunner

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt Brunner. A scholar is included among the top collaborators of Kurt Brunner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt Brunner. Kurt Brunner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Joss, R, et al.. (2008). Vindesin, ein neues Zytostatikum aus der Reihe der Vinca-Alkaloide. DMW - Deutsche Medizinische Wochenschrift. 105(26). 931–935.
2.
Brunner, Kurt. (2001). Die Kartographie im Deutschen Alpenverein. KN - Journal of Cartography and Geographic Information. 51(1). 17–22. 2 indexed citations
3.
Castiglione‐Gertsch, Monica, S. Pampallona, M. Varini, et al.. (1993). Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?. Annals of Oncology. 4(9). 735–740. 24 indexed citations
4.
Borner, Markus, M. Castiglione, J. Triller, et al.. (1992). Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Annals of Oncology. 3(2). 113–115. 17 indexed citations
5.
Borner, Markus, U Laffer, R. Obrist, et al.. (1990). Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. Annals of Oncology. 1(3). 227–228. 7 indexed citations
6.
Cerny, T., A Pedrazzini, R Joss, & Kurt Brunner. (1988). Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). European Journal of Cancer and Clinical Oncology. 24(11). 1791–1794. 24 indexed citations
7.
Pedrazzini, A, F. Cavalli, Kurt Brunner, Aron Goldhirsch, & Bernadette Mermillod. (1987). Complete Remission following Endocrine or Combined Cytotoxic and Hormonal Treatment in Advanced Breast Cancer. Oncology. 44(1). 51–59. 14 indexed citations
8.
Joss, R, et al.. (1985). Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy. European Journal of Clinical Pharmacology. 27(6). 721–725. 14 indexed citations
9.
Goldhirsch, Aron, Richard Greiner, E. Dreher, et al.. (1985). The Treatment of Ovarian Cancer by a Multimodality Approach: Remission Induction with Chemotherapy – Hexa PAMP and PAMP Regimens – Followed by Whole-abdominal Radiation. Oncology Research and Treatment. 8(6). 383–387. 5 indexed citations
10.
11.
Goldhirsch, Aron, R Joss, T.-M. Markwalder, Hugo Studer, & Kurt Brunner. (1983). Acute Cerebrovascular Accident after Treatment with Cis-Platinum and Methylprednisolone. Oncology. 40(5). 344–345. 19 indexed citations
12.
Joss, R, et al.. (1983). Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. European Journal of Clinical Pharmacology. 25(1). 35–39. 13 indexed citations
13.
14.
Cooper, M. Robert, Thomas F. Pajak, Nis I. Nissen, et al.. (1982). Effect of the methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer. 49(11). 2226–2230. 5 indexed citations
15.
Joss, R, et al.. (1982). Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemotherapy and Pharmacology. 9(1). 61–64. 6 indexed citations
16.
Cavalli, F., W. F. Jungi, & Kurt Brunner. (1981). Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen Mammakarzinom. Oncology Research and Treatment. 4(2). 80–83. 12 indexed citations
17.
18.
Cavalli, F, Roland Sonntag, & Kurt Brunner. (1977). ACUTE LEUKAEMIA IN HODGKIN'S DISEASE. Scandinavian Journal of Haematology. 19(3). 319–320. 5 indexed citations
19.
Sonntag, Roland, et al.. (1975). Treatment of metastatic testicular carcinoma with bleomycin (NSC-125066) used alone or in combination with CCNU (NSC-79037).. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 59(2 Pt 1). 429–31. 5 indexed citations
20.
Brunner, Kurt, et al.. (1971). [The oral administration of vitamin-A-acid in leukoplakias, hyperkeratoses and squamous cell carcinomas: results and tolerance].. PubMed. 101(28). 1027–30. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario V. Fiorentino Breakdown of academic impact, for papers by D.Th. Sleijfer Breakdown of academic impact, for papers by Stephen Shibata Breakdown of academic impact, for papers by P. Fargeot Breakdown of academic impact, for papers by Miriam Tucker Breakdown of academic impact, for papers by Robert M. OʼBryan Breakdown of academic impact, for papers by L H Einhorn Breakdown of academic impact, for papers by Jean-Pierre Droz Breakdown of academic impact, for papers by John F. Hannigan Breakdown of academic impact, for papers by H. Curé
Rankless by CCL
2026